Exscopia

Non-invasive Breath Decoder for Blood Glucose Metering

Health Tech & Life Sciences
Stealth Mode
Pre-Funding Israel Founded 2017
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2017
Headcount
6
HQ
Israel
Sector
Health Tech & Life Sciences

About

Exscopia develops a technology that observes the indicator gases in breath with unprecedented sensitivity, in real-time, in reasonable size and cost for personal and institutional use. The compan is offering an absolute measurement in several seconds, non-invasive small device for personal use along with clinics high performance instrument for multiple compounds simultaneously. Exscopia aims at making the life of diabetics effortless and simple.

Q&A

What is Exscopia's primary focus?
Exscopia develops a non-invasive breath decoder for blood glucose metering, aiming to make life easier for diabetics.
When was Exscopia founded?
Exscopia was founded in March 2017.
What is the current status of Exscopia?
Exscopia is currently inactive, having ceased operations in June 2019.
Who is the founder and CEO of Exscopia?
Michal Badash is the Founder & CEO of Exscopia.
In which sector does Exscopia primarily operate?
Exscopia's primary sector is Health Tech & Life Sciences.
What kind of technology does Exscopia offer?
Exscopia offers a technology that observes indicator gases in breath with high sensitivity for real-time, non-invasive measurements, suitable for personal and institutional use.

Team · 1

Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders

Tags

real-timenon-invasivemedical-devicesdiabetesstealthmode
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2017-3
Employees (exact)6
Status reasonNon Active, Jun 2019 ceased to operate